Last-Resort drug access opens for rare tumor patients

NCT ID NCT05028166

AVAILABLE Disease control Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This program provides mirdametinib to individual patients with serious, life-threatening conditions like neurofibromatosis type 1 tumors or other MAP-K pathway diseases who have no other treatment options and cannot join a clinical trial. Each case requires approval from the company, ethics board, and health authorities. The goal is to control the disease when standard treatments have failed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HISTIOCYTIC NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

histiocytic and dendritic cell neoplasm histiocytic sarcoma neurofibromatosis plexiform neurofibroma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HISTIOCYTIC NEOPLASM NEUROFIBROMATOSIS TYPE 1-ASSOCIATED PLEXIFORM NEUROFIBROMAS OTHER MAP-K PATHWAY DRIVEN DISEASES

More trials for these conditions

Other studies related to the condition(s) this trial covers.